Most of us know that medicines carry risks as well as rewards, but just how are they monitored?

‍

‍

This presentation by the European Medicines Agency does a fantastic job of explaining, in a straightforward way, how the safety of new covid19 drugs are monitored and recorded throughout each step of the drugdevelopment process.

—

Providing a full suite of pharmaceutical services for over two decades, QUINTA-ANALYTICA are market-leaders in drug testing, clinical studies, bioanalytical services & more.

Get in toush with us today to discuss how we can help support you.

‍

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

ALL POSTS